• Home
  • Pansupport
  • Cancer information
    • Pancreatic cancer
    • Liver cancer
    • Stomach cancer
    • Biliary cancer
    • Oesophageal cancer
    • Resources
    • Clinical trials
    • My Care KIT
  • Living well
    • Practical support
    • Emotional support
    • Support groups
    • Physical wellbeing
    • PanSupport Helpline
  • Advanced cancer care
    • Palliative care
    • Advance care planning
    • End-of-life considerations
    • Bereavement
  • Stories of Hope
  • Impressions of You
  • Cancer research
    • Our research strategy
    • Research programs we fund
    • Clinical trials
    • Research project grants and funding
    • Scholarships and awards
  • Get Involved
    • Fundraise for Pancare
    • Upcoming events
    • Business & corporate support
    • Volunteering with Pancare
    • Ways to give
  • Health professionals
  • About Us
    • What we do
    • Who we are
    • Strategic Plan
    • Annual reports
    • Strategic partners
    • State of the Nation
    • Cancer statistics
  • News
  • Shop
  • Contact Us
HELPLINE

CANCER SUPPORT

1300 881 698

LEARN MORE

CANCER SUPPORT | 1300 881 698

  • About us
  • PanSupport
  • For Health Professionals
  • Refer a Patient
  • News
  • Contact
Shop
Logo
  • Cancer information
  • Living well
  • Advanced cancer care
  • Cancer research
  • Get Involved
  • Donate

Home » Trial of radiation implant extends the life of metal biliary stents

October 7, 2021 by Mr Daniel Croagh

New radiation implant trial has important implications for the prevention of jaundice in liver and pancreatic cancer

Important implications for the prevention of jaundice in liver and pancreatic cancer

Key messages from Wang et al. World Journal of Clinical Cases 2021; 9(4): 801-11

  • This small randomised controlled trial examined the safety and efficacy of the use of micro-low-dose-rate irradiating iodine particles (iodine-125 seed strand implantation) with metal biliary stents to improve survival in patients with bile duct cancer (e.g. cholangiocarcinoma) or peri-ampullary cancer in the area surrounding the bile ducts near the opening to the small intestine or duodenum, which is called the ampulla of vater.
ampula of vater
  • The authors were aiming to understand whether the combination stent with iodine-125 seed strand implantation would prolong the time to stent dysfunction or failure and improve survival for those with obstructive jaundice, a common effect of these aggressive cancers.
  • The results were significant: the combined stent lasted longer than the stent alone (9 vs 6 months, respectively), and the group with the combined stent lived longer than the control group (11 vs 7 months, respectively).
  • Postoperative liver function improved in all patients, and there were no differences between the groups in terms of technical success of stenting, acute preoperative or postoperative outcomes, indicating that risk profiles of the combined and control stents were similar.
  • In summary, the combination of iodine-125 seed strand implantation combined with stenting was safe and effective in removing biliary blockage, improving liver function, prolonging the function of the stent and improving overall survival of those with malignant obstructive jaundice.

Discussion points from expert reviewer, Mr Daniel Croagh

One of the main problems for patients with pancreatic and biliary tract cancer is recurrent jaundice and infection due to biliary stent blockage. This can lead to significant reductions in survival. 

Much work has been done to improve stent patency including the use of metal as opposed to plastic stents and the use of covered vs uncovered stents.

There is still a lot of debate as to the best approach for these patients. In this recent, small single-centre randomised controlled trial (Wang et al. WJCC 2021), the addition of radioactive iodine strands to conventional metal stents was examined in patients with presumed malignant strictures secondary to hilar cholangiocarcinoma, gall bladder cancer, pancreatic cancer or malignant hilar lymphadenopathy.

The authors found longer stent patency and longer survival with the addition of radioactive iodine presumably due to the radiation resulting in less tumour in growth and less bile duct hyperplasia (overgrowth) at the end of the stents.

This is an interesting finding and deserves further investigation in larger and more homogeneous patient populations.

The area is likely to continue to evolve dramatically as improved systemic chemotherapy leads to longer-term survival, resulting in the need for stents that either maintain long-term patency or are capable of being replaced if needed.

About Mr Daniel Croagh, Pancare Medical Advisor

Mr Daniel Croagh, Pancare Medical Advisor

Daniel Croagh is a liver, pancreas and biliary surgeon working predominantly at Monash Medical Centre and Jessie Macpherson Private Hospital in Melbourne.

He undertook surgical training St Vincent’s Hospital during which time he also obtained a PhD in stem cell biology at Peter MacCallum Cancer Centre.

His Fellowship training was at Monash Medical Centre and the Liver Transplant Unit at the Queen Elizabeth Hospital in Birmingham, UK.

Mr Croagh’s areas of special interest include hepatobiliary endoscopy (endoscopic ultrasound and endoscopic retrograde cholangiopancreatography, ERCP), complex liver and pancreatic surgery for benign and malignant conditions, gall stone disease and severe pancreatitis.

He is also active in clinical and basic science research in his roles as a Senior Lecturer at Monash University and Director of Research for the department of upper gastrointestinal and hepatobiliary surgery at Monash Medical Centre.

Reference

Wang HW, Li XJ, Li SJ, Lu JR, He DF. Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice. World J Clin Cases 2021; 9(4): 801-811.


Read more . . .

Filed Under: Expert summary, News Tagged With: Expert Summary, Research

Previous

Pancare ‘Support, Save and Win’ promotion now has a winner

October 19, 2021

Next

Adding Value to scans with Pancare funded PURPLE Translational Registry Radiomics module

September 29, 2021

Latest News

  • What to do if there are Creon supply issues
  • Trek for Hope reaches new heights
  • Biliary cancer awareness campaign success
  • 2022 Pancare scholarship opportunities launch today
  • Pancare Foundation launches initiatives to help people diagnosed with rare biliary cancer
  • Living with pets when living with cancer
  • Pancare Foundation Annual Review 2021
  • Wins for pancreatic cancer clinical trials research

About Pancare

  • About us
  • What we do
  • Who we are
  • Strategic Plan
  • RACE Innovation Lab
  • Pancare Partners
  • State of the Nation
  • Cancer statistics
  • About us
  • PanSupport
  • Cancer research
  • Health professionals
  • Practical support
  • Get Involved
  • Shop
Pancare Foundation
  • 70 Yarra Street Heidelberg Victoria 3084 Australia
  • 1300 881 698

Privacy Policy

In the spirit of the reconciliation Pancare acknowledges the Traditional Custodians of the country throughout Australia, and their continuing connection to land, and sea and the community. We pay our respects to Aboriginal and Torres Strait Islander people and their cultures, and to Elders past, present and emerging.

Pancare Foundation
  • 70 Yarra Street Heidelberg Victoria 3084 Australia
  • 1300 881 698
  • Connect with Pancare
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram
    • YouTube
  • About us
  • PanSupport
  • Cancer research
  • Health professionals
    • Refer a Patient
  • Get Involved
    • Community Fundraising
    • Upcoming fundraising events
    • Volunteer With Us
    • Partnerships
  • Ways to give
  • Cancer Types
    • Pancreatic Cancer
    • Biliary Cancer
    • Oesophageal Cancer
    • Stomach Cancer
    • Liver Cancer
  • Stories of Hope
  • Support Services
    • Practical
    • Emotional
    • Physical
  • PanSupport Helpline
  • Support groups
  • Contact
  • News
  • Shop

Privacy Policy

The Pancare Foundation is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC). The Pancare Foundation has Deductible Gift Recipient (DGR) status with the Australian Tax Office. Donations over $2 or more are tax-deductible. ABN: 89 797 016 686

In the spirit of the reconciliation Pancare acknowledges the Traditional Custodians of the country throughout Australia, and their continuing connection to land, and sea and the community. We pay our respects to Aboriginal and Torres Strait Islander people and their cultures, and to Elders past, present and emerging.

We celebrate, value and include people of all backgrounds, genders, sexualities, cultures, bodies and abilities.

Copyright 2025 Website by AlphaSys